Fate Therapeutics Company Profile (NASDAQ:FATE)

About Fate Therapeutics

Fate Therapeutics logoFate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: FATE
  • CUSIP:
Key Metrics:
  • Previous Close: $2.66
  • 50 Day Moving Average: $2.24
  • 200 Day Moving Average: $1.91
  • 52-Week Range: $1.46 - $7.19
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.40
  • P/E Growth: 0.00
  • Market Cap: $76.86M
  • Outstanding Shares: 28,894,000
  • Beta: 0.79
Additional Links:
Companies Related to Fate Therapeutics:

Analyst Ratings

Consensus Ratings for Fate Therapeutics (NASDAQ:FATE) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.00 (163.16% upside)

Analysts' Ratings History for Fate Therapeutics (NASDAQ:FATE)
Show:
DateFirmActionRatingPrice TargetDetails
8/9/2016HC WainwrightReiterated RatingBuyView Rating Details
8/8/2016BMO Capital MarketsSet Price TargetBuy$4.00View Rating Details
6/21/2016Leerink SwannReiterated RatingOutperform$4.00View Rating Details
5/10/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
12/7/2015WedbushReiterated RatingOutperform$10.00View Rating Details
11/5/2015Cowen and CompanyReiterated RatingOutperformView Rating Details
10/6/2015Raymond James Financial Inc.Initiated CoverageOutperform$8.00View Rating Details
(Data available from 8/31/2014 forward)

Earnings

Earnings History for Fate Therapeutics (NASDAQ:FATE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2016        
8/8/2016Q216($0.32)($0.29)$1.02 million$1.03 millionViewN/AView Earnings Details
5/9/2016Q116($0.25)($0.29)ViewN/AView Earnings Details
3/3/2016Q415($0.27)($0.26)$1.10 millionViewN/AView Earnings Details
11/3/2015Q315($0.30)($0.24)$1.00 millionViewN/AView Earnings Details
8/5/2015Q215($0.39)($0.33)ViewN/AView Earnings Details
5/7/2015Q115($0.37)($0.38)ViewListenView Earnings Details
3/12/2015Q414($0.31)($0.30)ViewListenView Earnings Details
11/11/2014($0.29)($0.30)ViewN/AView Earnings Details
8/12/2014Q214($0.37)($0.30)ViewN/AView Earnings Details
5/13/2014Q114($0.33)($0.34)ViewN/AView Earnings Details
3/17/2014Q413($0.27)($0.29)ViewN/AView Earnings Details
11/13/2013Q3($0.32)($4.81)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Fate Therapeutics (NASDAQ:FATE)
Current Year EPS Consensus Estimate: $-1.12 EPS
Next Year EPS Consensus Estimate: $-1.11 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.31)($0.27)($0.29)
Q2 20162($0.35)($0.33)($0.34)
Q3 20163($0.35)($0.30)($0.33)
Q4 20163($0.36)($0.23)($0.31)
Q1 20171($0.36)($0.36)($0.36)
Q2 20171($0.38)($0.38)($0.38)
Q3 20171($0.40)($0.40)($0.40)
Q4 20171($0.30)($0.30)($0.30)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Fate Therapeutics (NASDAQ:FATE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Fate Therapeutics (NASDAQ:FATE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/12/2014Peter D FlynnInsiderSell6,488$7.00$45,416.00View SEC Filing  
6/10/2014Peter D FlynnInsiderSell3,305$7.00$23,135.00View SEC Filing  
5/1/2014Peter D FlynnInsiderSell9,793$7.07$69,236.51View SEC Filing  
4/4/2014Peter D FlynnInsiderSell5,889$8.00$47,112.00View SEC Filing  
4/2/2014Christian WeyerInsiderSell10,000$9.02$90,200.00View SEC Filing  
4/1/2014J Scott WolchkoInsiderSell20,000$9.64$192,800.00View SEC Filing  
3/31/2014Daniel D ShoemakerCTOSell8,653$9.86$85,318.58View SEC Filing  
10/4/2013John MendleinDirectorBuy16,667$6.00$100,002.00View SEC Filing  
10/4/2013Venture Fund Vi Lp ArchMajor ShareholderBuy833,333$6.00$4,999,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Fate Therapeutics (NASDAQ:FATE)
DateHeadline
capitalcube.com logoETF’s with exposure to Fate Therapeutics, Inc. : August 29, 2016 (NASDAQ:FATE)
www.capitalcube.com - August 29 at 4:53 PM
live-pr.com logoFate Therapeutics, Inc. (FATE) - Financial and Strategic SWOT Analysis Review - New Market Report (NASDAQ:FATE)
www.live-pr.com - August 22 at 9:37 AM
4-traders.com logoFate Therapeutics : Announces $10.3 Million Common Stock Private Placement (NASDAQ:FATE)
www.4-traders.com - August 20 at 9:10 AM
News IconInstitutions Have Decreased Their Ownership of Fate Therapeutics, Inc. (NASDAQ:FATE) - Post News (NASDAQ:FATE)
www.kentuckypostnews.com - August 19 at 6:22 AM
News IconFate Therapeutics, Inc.'s (FATE): Significant Runner - Hot Stocks Point - Hot Stocks Point (NASDAQ:FATE)
www.hotstockspoint.com - August 19 at 6:22 AM
publicnow.com logoFate Therapeutics Announces $10.3 Million Common Stock Private Placement (NASDAQ:FATE)
www.publicnow.com - August 19 at 6:22 AM
finance.yahoo.com logoFATE THERAPEUTICS INC Financials (NASDAQ:FATE)
finance.yahoo.com - August 17 at 5:08 PM
capitalcube.com logoETF’s with exposure to Fate Therapeutics, Inc. : August 12, 2016 (NASDAQ:FATE)
www.capitalcube.com - August 12 at 5:00 PM
capitalcube.com logoFate Therapeutics, Inc. :FATE-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 (NASDAQ:FATE)
www.capitalcube.com - August 11 at 5:06 PM
News IconMix Wondering Stocks- Celldex Therapeutics (NASDAQ:CLDX), Fate Therapeutics (NASDAQ:FATE), Zoetis (NYSE:ZTS) - Seneca Globe (NASDAQ:FATE)
www.senecaglobe.com - August 10 at 5:11 PM
News IconFate Therapeutics Inc (NASDAQ:FATE): Here's Our Take - Street Register (NASDAQ:FATE)
streetregister.com - August 10 at 5:11 PM
finance.yahoo.com logoFate Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference (NASDAQ:FATE)
finance.yahoo.com - August 10 at 5:11 PM
News IconHC Stocks Assessments: Perrigo Company plc Ordinary Shares (NYSE:PRGO), Fate Therapeutics Inc (NASDAQ:FATE) - share market updates (press release) (NASDAQ:FATE)
sharemarketupdates.com - August 9 at 3:40 PM
News IconBiotech Stocks To Put On Your Watch List: Fate Therapeutics, Inc. (NASDAQ:FATE), Array BioPharma Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:FATE)
voiceregistrar.com - August 9 at 3:40 PM
streetupdates.com logoLatest Analysts Tips Update: Galena Biopharma, Inc. (NASDAQ:GALE) , Fate Therapeutics, Inc. (NASDAQ:FATE) - Street Updates (NASDAQ:FATE)
www.streetupdates.com - August 9 at 3:40 PM
finance.yahoo.com logoFate Therapeutics (FATE) Jumps: Stock Moves 22.8% Higher (NASDAQ:FATE)
finance.yahoo.com - August 9 at 3:40 PM
4-traders.com logoFATE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) (NASDAQ:FATE)
www.4-traders.com - August 8 at 10:16 PM
sg.finance.yahoo.com logoFate Therapeutics reports 2Q loss (NASDAQ:FATE)
sg.finance.yahoo.com - August 8 at 10:16 PM
nasdaq.com logoFate Therapeutics Announces $10.3 Million Common Stock Private Placement - Nasdaq (NASDAQ:FATE)
www.nasdaq.com - August 8 at 5:04 PM
investors.com logoFate Therapeutics Inc raises US$10.3mln to develop ... - Proactive Investors USA & Canada (NASDAQ:FATE)
www.proactiveinvestors.com - August 8 at 5:04 PM
finance.yahoo.com logoFate Therapeutics Reports Second Quarter 2016 Financial Results (NASDAQ:FATE)
finance.yahoo.com - August 8 at 5:04 PM
biz.yahoo.com logoFATE THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh (NASDAQ:FATE)
biz.yahoo.com - August 8 at 5:04 PM
reuters.com logoBRIEF-Fate Therapeutics says $10.3 million common stock private placement (NASDAQ:FATE)
in.reuters.com - August 8 at 9:45 AM
investors.com logoFate Therapeutics raises US$10.3mln to develop immunotherapy pipeline (NASDAQ:FATE)
www.proactiveinvestors.com - August 8 at 9:45 AM
twst.com logoJuno Therapeutics Inc.: Juno Therapeutics Reports Second Quarter 2016 Financial Results (NASDAQ:FATE)
www.twst.com - August 4 at 10:44 PM
tmcnet.com logoJuno Therapeutics Reports Second Quarter 2016 Financial Results (NASDAQ:FATE)
www.tmcnet.com - August 4 at 5:16 PM
biz.yahoo.com logoJuno Therapeutics Inc Earnings Call (Q2 2016) (NASDAQ:FATE)
biz.yahoo.com - August 4 at 6:14 AM
finance.yahoo.com logoFate Therapeutics to Webcast Conference Call Reporting Second Quarter 2016 Financial Results on August 8, 2016 (NASDAQ:FATE)
finance.yahoo.com - August 2 at 5:10 PM
streetupdates.com logoAnalysts Rating updates about two Stocks: Boston Scientific Corporation (NYSE:BSX) , Fate Therapeutics, Inc ... - Street Updates (NASDAQ:FATE)
www.streetupdates.com - July 30 at 6:28 AM
News IconTrading the Biotech News: Fate Therapeutics, Inc. (NASDAQ:FATE), Cerus Corporation (NASDAQ:CERS) - The Voice Registrar (NASDAQ:FATE)
voiceregistrar.com - July 30 at 6:28 AM
fortune.com logoFate Therapeutics, Inc. (NASDAQ:FATE) Insider Activities Are in the Air - Review Fortune (NASDAQ:FATE)
reviewfortune.com - July 30 at 6:28 AM
News IconEarnings Estimates Spotlight: Fate Therapeutics, Inc. (NASDAQ:FATE) - News Oracle (NASDAQ:FATE)
www.newsoracle.com - July 30 at 6:28 AM
sbwire.com logoGraft vs. Host Disease - Competitive Landscape, Technology and Pipeline Analysis, 2016; New Report Launched (NASDAQ:FATE)
www.sbwire.com - July 29 at 12:00 PM
kcregister.com logoBiotech Gainers in Focus: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), Fate Therapeutics, Inc. (NASDAQ:FATE ... - KC Register (NASDAQ:FATE)
www.kcregister.com - July 28 at 3:42 PM
reuters.com logoBRIEF-Fate Therapeutics receives patent for human induced pluripotent cells - Reuters (NASDAQ:FATE)
www.reuters.com - July 27 at 7:32 AM
globenewswire.com logoFate Therapeutics Announces Issuance of U.S. Patent on Compositions of Human Induced Pluripotent Cells - GlobeNewswire (press release) (NASDAQ:FATE)
globenewswire.com - July 26 at 11:05 PM
finance.yahoo.com logo8:03 am Fate Therapeutics announces issuance of U.S. Patent covering preparations of human induced pluripotent cells (NASDAQ:FATE)
finance.yahoo.com - July 26 at 8:03 AM
finance.yahoo.com logoFate Therapeutics Announces Issuance of U.S. Patent on Compositions of Human Induced Pluripotent Cells (NASDAQ:FATE)
finance.yahoo.com - July 26 at 8:01 AM
openpr.com logoMarket Forecast Report on Regenerative Medicine, 2016-2026 (NASDAQ:FATE)
www.openpr.com - July 25 at 9:38 AM
News IconIncreased Volatility Noted on Shares of: Fate Therapeutics, Inc. (NASDAQ:FATE) - Engelwood Daily (NASDAQ:FATE)
www.engelwooddaily.com - July 23 at 9:02 AM
News IconEquity Roundup: Stock Performance Focus on Fate Therapeutics, Inc. (NASDAQ:FATE) - Press Telegraph (NASDAQ:FATE)
presstelegraph.com - July 23 at 9:02 AM
News IconInvestor Update: Earnings and Target Price Recap on Fate Therapeutics, Inc. (NASDAQ:FATE) - Press Telegraph (NASDAQ:FATE)
presstelegraph.com - July 22 at 6:32 AM
News IconHochman Cole Investment Advisors Lowers stake in Fate Therapeutics Inc (FATE) - TheFounders Daily (NASDAQ:FATE)
www.thefoundersdaily.com - July 21 at 8:30 AM
News IconIncreased Stock Volatility Watch: Fate Therapeutics, Inc. (NASDAQ:FATE) - Engelwood Daily (NASDAQ:FATE)
www.engelwooddaily.com - July 20 at 6:17 PM
News IconFate Therapeutics, Inc. (NASDAQ:FATE): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:FATE)
www.engelwooddaily.com - July 20 at 6:17 PM
news.cmlviz.com logoFate Therapeutics Inc Stock Technicals Hit Weakness - CML News (NASDAQ:FATE)
news.cmlviz.com - July 20 at 6:17 PM
News IconStock Moving Lower for the Month; Investor Update on Fate Therapeutics, Inc. (NASDAQ:FATE) - Engelwood Daily (NASDAQ:FATE)
www.engelwooddaily.com - July 20 at 6:28 AM
News IconHC Stocks Newsbeat: Perrigo Company plc Ordinary Shares (NYSE:PRGO), Fate Therapeutics Inc (NASDAQ:FATE) - share market updates (press release) (NASDAQ:FATE)
sharemarketupdates.com - July 19 at 5:04 PM
kcregister.com logoStocks to Watch: Fate Therapeutics, Inc. (NASDAQ:FATE), The Coca-Cola Company (NYSE:KO), Lam Research ... - KC Register (NASDAQ:FATE)
www.kcregister.com - July 19 at 11:05 AM
News IconFate Therapeutics, Inc. (NASDAQ:FATE) Wall Street Analyst Recommendation Outlook - TGP (NASDAQ:FATE)
telanaganapress.com - July 19 at 11:05 AM

Social

Fate Therapeutics (NASDAQ:FATE) Chart for Wednesday, August, 31, 2016


Last Updated on 8/31/2016 by MarketBeat.com Staff